Form 4: Cidara Therapeutics Director Granted Stock Options to Align Interests

Cidara Therapeutics, Inc. Director Carin Canale-Theakston was granted 11,100 stock options with an exercise price of $21.31, vesting by June 2026.

Summary

• Carin Canale-Theakston, a Director of Cidara Therapeutics, Inc. (CDTX), was granted 11,100 stock options.
• The stock options have an exercise price of $21.31 per share.
• The grant date for these options was June 18, 2025.
• The options are scheduled to vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 17, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of alignment between management and shareholder interests, indicating a commitment to long-term value creation. It is a routine compensation event, not indicative of significant operational changes, hence a moderately positive score.

Positives

• The grant of 11,100 stock options to Director Carin Canale-Theakston aligns her interests with those of shareholders, incentivizing long-term performance and value creation for Cidara Therapeutics.

Future Outlook

The stock options granted to Director Carin Canale-Theakston are set to vest by June 2026, aligning her incentives with the company's future performance and long-term shareholder value creation.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and incentivize key personnel by aligning their financial interests with the long-term success and stock performance of the company.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, including those in the biotechnology sector like Cidara Therapeutics.
• While the specific number of options (11,100) and exercise price ($21.31) are company-specific, the mechanism of using equity-based compensation to incentivize directors is consistent with industry benchmarks for corporate governance and executive alignment.
• No specific comparable companies or projects are mentioned in the filing to provide a detailed comparison.

Corporate Governance

Related Party Transactions

• The grant of stock options to Carin Canale-Theakston, a Director of Cidara Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with shareholders, potentially leading to better long-term performance and value creation.

Next Steps

• The granted stock options will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 annual meeting of stockholders.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Stock Option, Director, Insider Transaction, Form 4, Equity Grant, Executive Compensation